Analysis of Differentiation Protocols Defines a Common Pancreatic Progenitor Molecular Signature and Guides Refinement of Endocrine Differentiation
Year: 2019
Type: article
Abstract: Several distinct differentiation protocols for deriving pancreatic progenitors (PPs) from human pluripotent stem cells have been described, but it remains to be shown how similar the PPs are across protocols and how well they resemble their in vivo counterparts. Here, we evaluated three differentiation protocols, performed RNA and assay for transposase-accessible chromatin using sequencing on isolated PPs derived with these, and compared them with fetal human pancreas populations. This enabled us to define a shared transcriptional and epigenomic signature of the PPs, including several genes not previously implicated in pancreas development. Furthermore, we identified a significant and previously unappreciated cross-protocol variation of the PPs through multi-omics analysis and demonstrate how such information can be applied to refine differentiation protocols for derivation of insulin-producing beta-like cells. Together, our study highlights the importance of a detailed characterization of defined cell populations derived from distinct differentiation protocols and provides a valuable resource for exploring human pancreatic development.
Source: Stem Cell Reports
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
Funders: Boehringer Ingelheim, Eli Lilly and Company, Pfizer, AstraZeneca, Merck, Roche, Sanofi, AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical Company, Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, National Institute for Health and Care Research, University of Oxford, European Commission, Novo Nordisk, Takeda Medical Research Foundation, Novo Nordisk Fonden, Innovative Medicines Initiative, Servier, National Institutes of Health, Horizon 2020 Framework Programme, Medical Research Council, Seventh Framework Programme, NIHR Oxford Biomedical Research Centre, National Institute of Diabetes and Digestive and Kidney Diseases, Janssen Biotech, Janssen Pharmaceuticals
Awards: G1010233069, G1080657738, Human Genetics and Disease Biology: Core Renewal for the Wellcome Trust Centre for Human Genetics, Large-scale data integration to advance mechanistic inference and precision medicine in type 2 diabetes, G1335979935, G220799409, Characterising causal alleles for common disease., Bridging the gap from type 2 diabetes genetics to functional mechanisms of disease., G363194132, G3797955763, G3873106536, Understanding Mechanisms of Beta-Cell Dysfunction using Genome Engineering in Human-Derived Induced Pluripotent Stem Cells, Identifying variants causal for Type 2 Diabetes in Major human populations, G4426574518, Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC), G5399775027, Integrating genome-scale data to reveal causal mechanisms in type 2 diabetes, G5612337485, G5846212695, Defining the molecular and physiological mechanisms of pancreatic islet dysfunction which lead to type 2 diabetes, G63770550, G6723475937, Understanding the genetic basis of common human diseases: core funding for the Wellcome Trust Centre for Human Genetics., G7079742530, G729486055, Human Genetics and Disease Biology: Core Renewal for the Wellcome Trust Centre for Human Genetics, Defining mechanisms for pancreatic beta-cell dysfunction in type 2 diabetes, A systematic approach to understanding the biology underpinning GWAS hits., NIHR Senior Investigator Award, G867345008, G8975541179
OpenAlex ID: W2997946728
